Oncology, cancer prevention, tumor biology, and immunotherapy relevant to longevity
1,158 articles
A major trial found fewer statin recommendations and better adherence with heart scans, but did not establish equivalent cardiovascular protection.
A bacterium from a Japanese tree frog's gut cleared every colon tumor in mice after one IV dose, outperforming anti-PD-L1 and doxorubicin in the model.
Leukemia cells with low FDX1 resist copper-driven cell death. Blocking the metabolic enzyme ME1 restored sensitivity to the copper ionophore elesclomol in lab models.
A new ZDHHC2 inhibitor, TTZ1, restores ACSL4 and triggers ferroptosis, re-sensitizing resistant prostate tumors to enzalutamide in cell and mouse models.
In ferroptosis-sensitive cancer cells, nuclear actin filaments form as cells acidify, and alkaline conditions block them. They appear to be a side effect of ferroptosis, not a cause.
A CRISPR screen shows riboflavin stabilizes FSP1, a shield against ferroptosis. The riboflavin analog roseoflavin disables it and sensitizes cancer cells to ferroptosis.
Across 12 mouse diet models, anti-PD-1 response varied with diet but showed no significant association with metabolic measures. Separately, L. johnsonii plus an obesogenic diet promoted tumor regression in germ-free mice.
A Japanese phase I-II trial pairs antibiotics and donor stool transplant with checkpoint inhibitors in advanced esophageal and gastric cancer.
Japanese scientists found a compound that shields muscle-repair protein HGF from age-related damage and more than doubles its receptor binding in early mouse studies.
RIKEN researchers use the carbon monoxide that tumor cells make to trigger a palladium catalyst that builds toxic drugs inside the cancer cells, sparing healthy ones.
An antibody against myostatin, the muscle-growth brake, preserved bone, built muscle and cut bone tumor burden in breast cancer mouse models.
A CA Cancer J Clin review shows how ESR1, PIK3CA and RB1 changes, RNA subtypes and patient preferences now guide each step of HR-positive/HER2-negative metastatic breast cancer care.
